RCE.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:10):

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom...

Stats
Today's Volume	646 688
Average Volume	145 168
Market Cap	108.09M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.83
ATR14	$0.00600 (1.13%)

Recce Pharmaceuticals Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Recce Pharmaceuticals Ltd Correlation - Currency/Commodity

-0.51
( weak negative )

-0.58
( weak negative )

0.00
( neutral )

0.67
( moderate )

Recce Pharmaceuticals Ltd Financials

Annual	2023
Revenue:	$4.37M
Gross Profit:	$4.15M (95.03 %)
EPS:	$-0.0744

Q2	2023
Revenue:	$0
Gross Profit:	$-193 283 (0.00 %)
EPS:	$-0.0416

Q4	2023
Revenue:	$4.37M
Gross Profit:	$4.22M (96.75 %)
EPS:	$-0.0214

Q3	2022
Revenue:	$2.18M
Gross Profit:	$575 477 (26.37 %)
EPS:	$-0.0112

Financial Reports:

No articles found.

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.